Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 12 mechanisms across 30 industry trials with a known mechanism of action.

See full pipeline →

CD19/CD3

14 trials 4 active 2 sponsors

CD22-directed Immunoconjugate

4 trials 1 active 1 sponsor

BCL-2 Inhibitor

1 trials 1 active 1 sponsor

Menin Inhibitor

1 trials 1 active 1 sponsor

DNA

2 trials 2 sponsors

Nucleoside Metabolic Inhibitor

2 trials 2 sponsors

Factor Xa Inhibitor

1 trials 1 sponsor

Asparagine-specific Enzyme

1 trials 1 sponsor

DNA polymerase alpha/DNA primase/Ribonucleotide reductase

1 trials 1 sponsor

Kinase Inhibitor

1 trials 1 sponsor

Alkylating Drug

1 trials 1 sponsor

Proteasome Inhibitor

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

182 industry-sponsored trials across 100 sponsors

Showing 4 of 4 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Pfizer	inotuzumab ozogamicin	CD22-directed Immunoconjugate [EPC]	COMPLETED	2024-08-07	NCT05687032
Novartis	Nilotinib	—	COMPLETED	2023-07-07	NCT01735955
Pfizer	inotuzumab ozogamicin-dose level 2	—	COMPLETED	2022-09-21	NCT03677596
Amgen	Blinatumomab	CD19/CD3	TERMINATED	2024-07-04	NCT04506086

Showing 20 of 20 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Novartis	CTL019	—	RECRUITING	2027-03-31	NCT04094311
Merck	MK-1045	—	RECRUITING	2029-02-10	NCT07570173
AbbVie	Venetoclax	BCL-2 Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-08	NCT03844048
Amgen	Blinatumomab	CD19/CD3	ACTIVE NOT RECRUITING	2029-09-07	NCT04994717
Takeda	Ponatinib	—	ACTIVE NOT RECRUITING	2022-08-12	NCT03589326
Amgen	Blinatumomab	CD19/CD3	NOT YET RECRUITING	2030-05-10	NCT07223190
Jazz Pharmaceuticals	IM JZP-458	—	COMPLETED	2022-07-13	NCT04145531
Bristol-Myers Squibb	Apixaban	Factor Xa Inhibitor [EPC]	COMPLETED	2021-07-07	NCT02369653
Gamida Cell ltd	NiCord® (omidubicel)	—	COMPLETED	2021-04-29	NCT02730299
Novartis	CTL019	—	COMPLETED	2020-10-13	NCT03123939
Amgen	Blinatumomab	CD19/CD3	COMPLETED	2019-08-21	NCT03476239
Mesoblast, Ltd.	Infusion of one MPC expanded cord unit and one unexpanded cord unit	—	COMPLETED	2016-09-23	NCT01854567
Pfizer	inotuzumab ozogamicin	CD22-directed Immunoconjugate [EPC]	COMPLETED	2016-03-08	NCT01564784
ERYtech Pharma	GRASPA	—	COMPLETED	2014-09	NCT01518517
medac GmbH	asparaginase	Asparagine-specific Enzyme [EPC]	COMPLETED	2012-10	NCT00784017
Kiadis Pharma	ATIR101	—	TERMINATED	2021-11-09	NCT02999854
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Efprezimod alfa	—	TERMINATED	2021-11-05	NCT04095858
Amgen	Blinatumomab	CD19/CD3	TERMINATED	2015-12-29	NCT02013167
Spectrum Pharmaceuticals, Inc	Vincristine Sulfate Liposomes Injection (VSLI)	—	TERMINATED	2015-11	NCT01439347
Novartis	Tisagenlecleucel	—	WITHDRAWN	2025-10-08	NCT03628053

Showing 87 of 87 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Ossium Health, Inc.	—	—	RECRUITING	2026-05-31	NCT05589896
Cellectis S.A.	UCART22	—	RECRUITING	2026-06-30	NCT04150497
AstraZeneca	AZD0486	—	RECRUITING	2026-11-13	NCT06137118
Wugen, Inc.	WU-CART-007	—	RECRUITING	2026-12-30	NCT06514794
Excyte Biopharma Ltd	YK012	—	RECRUITING	2026-12-31	NCT06580301
Beijing Biotech	Autologous CD19/CD22 dual-target CAR-T module	—	RECRUITING	2027-03-14	NCT07523555
Vironexis Biotherapeutics Inc.	—	—	RECRUITING	2027-06	NCT06533579
Amgen	Blinatumomab	CD19/CD3	RECRUITING	2027-11-24	NCT04521231
Syndax Pharmaceuticals	revumenib	—	RECRUITING	2027-12-15	NCT04065399
Incyte Biosciences International Sàrl	Ponatinib	—	RECRUITING	2028-02-01	NCT03934372
AstraZeneca	—	—	RECRUITING	2028-04-28	NCT07109219
MSD R&D (China) Co., Ltd.	MK-1045	—	RECRUITING	2028-06-30	NCT05579132
BIOHENG THERAPEUTICS US LLC	CTD402 CAR T Cell Injection	—	RECRUITING	2028-09-30	NCT07070219
Merck	Zilovertamab vedotin	—	RECRUITING	2029-03-31	NCT06395103
Pfizer	Inotuzumab ozogamicin	CD22-directed Immunoconjugate [EPC]	RECRUITING	2033-10-31	NCT05748171
Beijing Yongtai Ruike Biotechnology Company Ltd	CAR-T-19 cell injection	—	RECRUITING	2025-06-30	NCT06179524
Juventas Cell Therapy Ltd.	single dose of CNCT19	—	RECRUITING	2025-05-30	NCT05667506
Shenzhen TargetRx Co., Ltd.	TGRX-814	—	RECRUITING	2025-02-28	NCT06206174
Chongqing Precision Biotech Co., Ltd	pCAR-19B cells	—	RECRUITING	2024-12-31	NCT05334823
Juventas Cell Therapy Ltd.	single dose of CNCT19	—	RECRUITING	2022-09-22	NCT04684147
Novartis	Rapcabtagene autoleucel single agent	—	ACTIVE NOT RECRUITING	2027-06-30	NCT03960840
Kura Oncology, Inc.	Ziftomenib	Menin Inhibitor [EPC]	ACTIVE NOT RECRUITING	2028-10-16	NCT04067336
Amgen	Blinatumomab	CD19/CD3	ACTIVE NOT RECRUITING	2028-12-05	NCT07134088
Autolus Limited	AUTO1	—	ACTIVE NOT RECRUITING	2029-06-30	NCT04404660
Amgen	Blinatumomab	CD19/CD3	ACTIVE NOT RECRUITING	2026-01-05	NCT06054113
Kite, A Gilead Company	KTE-X19	—	ACTIVE NOT RECRUITING	2025-11-20	NCT06253663
Novartis	CTL019	—	ACTIVE NOT RECRUITING	2025-08-20	NCT03876769
Otsuka Beijing Research Institute	Ponatinib 30mg OD	—	ACTIVE NOT RECRUITING	2022-07-22	NCT04233346
Bellicum Pharmaceuticals	BPX-501 T cells	—	ACTIVE NOT RECRUITING	2021-05-11	NCT03301168
Bellicum Pharmaceuticals	BPX-501 dose 1	—	ACTIVE NOT RECRUITING	2019-10-09	NCT01744223
Novartis	Asciminib Adult formulation	—	NOT YET RECRUITING	2033-07-18	NCT07387926
Kite, A Gilead Company	Brexucabtagene Autoleucel (KTE-X19)	—	COMPLETED	2026-03-25	NCT02625480
TCR2 Therapeutics	TC-110 T Cells	—	COMPLETED	2023-02-24	NCT04323657
Kite, A Gilead Company	brexucabtagene autoleucel	—	COMPLETED	2022-07-23	NCT02614066
Fate Therapeutics	ProTmune	—	COMPLETED	2020-12-04	NCT02743351
Autolus Limited	AUTO3 (CD19/22 CAR T cells	—	COMPLETED	2020-05-18	NCT03289455
Incyte Corporation	Ponatinib	—	COMPLETED	2020-04-24	NCT01641107
Novartis	CTL019	—	COMPLETED	2020-01-21	NCT02435849
Amgen	Blinatumomab	CD19/CD3	COMPLETED	2019-02-06	NCT02412306
Ariad Pharmaceuticals	Ponatinib	—	COMPLETED	2018-12-20	NCT01207440
Nohla Therapeutics, Inc.	Cyclophosphamide	DNA	COMPLETED	2018-09-18	NCT01690520
Ariad Pharmaceuticals	ponatinib - Phase 1	—	COMPLETED	2018-08-02	NCT01667133
Kiadis Pharma	ATIR101	—	COMPLETED	2018-07	NCT02500550
Novartis	CTL019 T-cells	—	COMPLETED	2018-05-29	NCT02228096
Eli Lilly	LY3039478	—	COMPLETED	2018-01-15	NCT02518113
BioSight Ltd.	Astarabine (BST-236)	—	COMPLETED	2017-09-20	NCT02544438
Gamida Cell ltd	NiCord®	—	COMPLETED	2017-06	NCT01816230
Delta-Fly Pharma, Inc.	DFP-10917	—	COMPLETED	2017-01-18	NCT01702155
Novartis	HSC835	—	COMPLETED	2016-10-03	NCT01474681
Sellas Life Sciences Group	Galinpepimut-S	—	COMPLETED	2016-09-30	NCT01266083
Novartis	HSC835	—	COMPLETED	2016-08-29	NCT01930162
Kiadis Pharma	ATIR	—	COMPLETED	2016-06	NCT01794299
Polyphor Ltd.	POL6326	—	COMPLETED	2015-11	NCT01413568
Jazz Pharmaceuticals	CPX-351	—	COMPLETED	2015-05	NCT02238925
Cellerant Therapeutics	human myeloid progenitor cells	—	COMPLETED	2014-11	NCT01297543
Nohla Therapeutics, Inc.	fludarabine phosphate	DNA polymerase alpha/DNA primase/Ribonucleotide reductase	COMPLETED	2014-08	NCT01175785
Pfizer	Inotuzumab Ozogamicin	CD22-directed Immunoconjugate [EPC]	COMPLETED	2014-08	NCT01363297
Amgen Research (Munich) GmbH	Blinatumomab	CD19/CD3	COMPLETED	2014-08	NCT01471782
Amgen Research (Munich) GmbH	Blinatumomab	CD19/CD3	COMPLETED	2014-02	NCT01207388
Traws Pharma, Inc.	rigosertib	—	COMPLETED	2013-12	NCT01167166
Amgen Research (Munich) GmbH	Blinatumomab	CD19/CD3	COMPLETED	2013-10	NCT01466179
Jazz Pharmaceuticals	asparaginase Erwinia chrysanthemi	—	COMPLETED	2013-08	NCT01643408
Gamida Cell ltd	NiCord®	—	COMPLETED	2012-09	NCT01221857
Betta Pharmaceuticals Co., Ltd.	Clofarabine	Nucleoside Metabolic Inhibitor [EPC]	COMPLETED	2011-11	NCT02544789
ERYtech Pharma	GRASPA	—	COMPLETED	2011-01	NCT01523782
Amgen Research (Munich) GmbH	Blinatumomab (MT103)	—	COMPLETED	2009-09	NCT00560794
Roche	Idasanutlin	—	TERMINATED	2024-05-06	NCT04029688
Takeda	Ponatinib	—	TERMINATED	2023-12-19	NCT04501614
Sanofi	Isatuximab	—	TERMINATED	2022-09-12	NCT03860844
Novartis	Tisagenlecleucel	—	TERMINATED	2021-10-19	NCT04225676
Ensoma	MGTA-145	—	TERMINATED	2021-09-14	NCT04762875
OncoTherapy Science, Inc.	OTS167IV	—	TERMINATED	2021-05	NCT02795520
Bellicum Pharmaceuticals	Rimiducid	—	TERMINATED	2020-06-30	NCT03733249
Bellicum Pharmaceuticals	BPX-501 T cells	—	TERMINATED	2020-06	NCT02065869
Gilead	Entospletinib	—	TERMINATED	2018-11-16	NCT02404220
Juno Therapeutics, a Subsidiary of Celgene	JCAR015 (CD19-targeted CAR T cells)	—	TERMINATED	2017-04-24	NCT02535364
Celldex Therapeutics	CDX-301	—	TERMINATED	2016-03	NCT02200380
MorphoSys AG	MOR00208 (formerly Xmab5574)	—	TERMINATED	2015-03	NCT01685021
Jazz Pharmaceuticals	pegcrisantaspase	—	TERMINATED	2015-02	NCT02257684
Novartis	midostaurin	Kinase Inhibitor [EPC]	TERMINATED	2014-09	NCT00866281
Texas Oncology Cancer Center	Busulfan	Alkylating Drug [EPC]	TERMINATED	2013-11	NCT01500161
Juventas Cell Therapy Ltd.	HY004	—	WITHDRAWN	2026-12-30	NCT06009107
Guangzhou Bio-gene Technology Co., Ltd	CD7 CAR-T	—	WITHDRAWN	2028-08-01	NCT05909527
Novartis	Tisagenlecleucel	—	WITHDRAWN	2022-11-30	NCT04156659
Matinas BioPharma Nanotechnologies, Inc.	Oral Encochleated Amphotericin B (CAMB)	—	WITHDRAWN	2020-12	NCT03187691
Jazz Pharmaceuticals	CPX-351	—	WITHDRAWN	2017-06	NCT02269579
Jazz Pharmaceuticals	Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)	—	WITHDRAWN	2015-06	NCT02150928

Showing 71 of 71 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Johnson & Johnson	14C-bleximenib	—	RECRUITING	2026-06-14	NCT07295951
Meryx, Inc.	MRX-2843	—	RECRUITING	2026-07	NCT04872478
PersonGen BioTherapeutics (Suzhou) Co., Ltd.	LV009 Injection	—	RECRUITING	2026-12-03	NCT07284927
Newave Pharmaceutical Inc	LP-118	—	RECRUITING	2026-12-31	NCT04771572
Imugene Limited	Azer-cel	—	RECRUITING	2027-06	NCT03666000
Autolus Limited	AUTO1	—	RECRUITING	2027-11	NCT06173518
OneChain Immunotherapeutics	CD1a-CAR T	—	RECRUITING	2027-12	NCT05679895
Orca Biosystems, Inc.	OrcaGraft (Orca-Q)	—	RECRUITING	2027-12	NCT03802695
Chongqing Precision Biotech Co., Ltd	Invivo CAR-T	—	RECRUITING	2027-12-31	NCT07239323
TriArm Therapeutics (Taiwan) Limited	ARM011	—	RECRUITING	2028-04-01	NCT07066397
Ascentage Pharma Group Inc.	Ascentage Pharma HQP1351 bioavailable inhibitor	—	RECRUITING	2029-12-27	NCT04260022
Tr1X, Inc.	TRX103	—	RECRUITING	2026-04-15	NCT06462365
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.	B019	—	RECRUITING	2026-01-31	NCT06927466
FamiCordTx	FCTX-CL19-1 (Tarcidomgen Kimleucel)	—	RECRUITING	2025-06	NCT06593145
Vincerx Pharma, Inc.	VIP943 (QW)	—	RECRUITING	2025-05-30	NCT06034275
Miltenyi Biomedicine GmbH	MB-CART19.1	—	ACTIVE NOT RECRUITING	2026-06	NCT03853616
Novartis	PIT565	—	ACTIVE NOT RECRUITING	2026-08-20	NCT05397496
PeproMene Bio, Inc.	BAFFR-CAR T cells	—	ACTIVE NOT RECRUITING	2026-11-18	NCT04690595
Sichuan Baili Pharmaceutical Co., Ltd.	GNC-038	—	ACTIVE NOT RECRUITING	2025-12	NCT04606433
Fate Therapeutics	FT819	—	ACTIVE NOT RECRUITING	2025-06-18	NCT04629729
Nkarta, Inc.	NKX019	—	ACTIVE NOT RECRUITING	2025-03-31	NCT05020678
Chongqing Precision Biotech Co., Ltd	MC-1-50	—	NOT YET RECRUITING	2027-11-01	NCT06641024
Allterum Therapeutics, Inc	4A10	—	NOT YET RECRUITING	2028-05	NCT07586618
Guangdong Ruishun Biotech Co., Ltd	RS001 injection	—	NOT YET RECRUITING	2026-04-01	NCT06894693
Newave Pharmaceutical Inc	LP-108	—	COMPLETED	2025-12-19	NCT04139434
Amgen	Blinatumomab	CD19/CD3	COMPLETED	2025-07-30	NCT06649006
Kymera Therapeutics, Inc.	KT-253	—	COMPLETED	2024-12-18	NCT05775406
Wugen, Inc.	WU-CART-007	—	COMPLETED	2024-08-08	NCT04984356
Syndax Pharmaceuticals	Revumenib	—	COMPLETED	2024-07-29	NCT05326516
Amgen	Carfilzomib	Proteasome Inhibitor [EPC]	COMPLETED	2024-06-28	NCT02303821
AbbVie	chemotherapy	—	COMPLETED	2023-04-19	NCT03236857
Amgen	Blinatumomab	CD19/CD3	COMPLETED	2023-01-24	NCT04524455
Shanghai Simnova Biotechnology Co.,Ltd.	CAR-NK-CD19 Cells	—	COMPLETED	2022-11-25	NCT05563545
AstraZeneca	AZD4573	—	COMPLETED	2021-09-30	NCT03263637
Xencor, Inc.	XmAb14045	—	COMPLETED	2021-09	NCT02730312
Chongqing Precision Biotech Co., Ltd	pCAR-19B cells	—	COMPLETED	2021-06-29	NCT04888468
Novartis	Asciminib (ABL001)	—	COMPLETED	2021-06-03	NCT02081378
Hebei Senlang Biotechnology Inc., Ltd.	CD7 CAR-T	—	COMPLETED	2021-05-30	NCT04572308
Jazz Pharmaceuticals	CPX-351	—	COMPLETED	2021-05-26	NCT03555955
Angiocrine Bioscience	Unmanipulated Umbilical Cord Blood (UCB)	—	COMPLETED	2020-12-21	NCT03483324
Juventas Cell Therapy Ltd.	single dose of CNCT19	—	COMPLETED	2020-12-01	NCT04230473
AbbVie	Navitoclax	—	COMPLETED	2020-11-11	NCT03181126
Bio-Path Holdings, Inc.	BP1001	—	COMPLETED	2017-03-30	NCT01159028
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	OTX015/Birabresib	—	COMPLETED	2017-01-20	NCT01713582
Calithera Biosciences, Inc	CB-839	—	COMPLETED	2016-10	NCT02071927
Epizyme, Inc.	EPZ-5676	—	COMPLETED	2016-05	NCT02141828
Tragara Pharmaceuticals, Inc.	TG02 citrate	—	COMPLETED	2016-03	NCT01204164
Epizyme, Inc.	EPZ-5676	—	COMPLETED	2015-11	NCT01684150
Novartis	Nilotinib	—	COMPLETED	2015-07-01	NCT01077544
MedImmune LLC	CAT-8015 (Moxetumomab Pasudotox)	—	COMPLETED	2014-12	NCT00659425
Traws Pharma, Inc.	ON 01910.Na	—	COMPLETED	2014-11	NCT00854646
Fate Therapeutics	Single FT1050 treated UCB unit	—	COMPLETED	2013-10	NCT01527838
Threshold Pharmaceuticals	TH-302	—	COMPLETED	2013-08	NCT01149915
Millennium Pharmaceuticals, Inc.	MLN4924	—	COMPLETED	2013-08	NCT00911066
AbbVie (prior sponsor, Abbott)	ABT-348	—	COMPLETED	2013-06	NCT01110473
Nova Laboratories Limited	Mercaptopurine 20mg/ml oral suspension	—	COMPLETED	2012-11	NCT01697020
Millennium Pharmaceuticals, Inc.	TAK-901	—	COMPLETED	2012-09	NCT00807677
Genzyme, a Sanofi Company	Clofarabine	Nucleoside Metabolic Inhibitor [EPC]	COMPLETED	2011-05	NCT01196013
Synta Pharmaceuticals Corp.	STA-9090 (ganetespib)	—	COMPLETED	2010-12	NCT00964873
Biomea Fusion Inc.	BMF-219	—	TERMINATED	2025-02-13	NCT05153330
Eden BioCell Ltd.	RPM CD19-mbIL15-CAR-T cells	—	TERMINATED	2022-05-12	NCT04844086
Tarix Pharmaceuticals	TXA127 300 mcg/kg/day	—	TERMINATED	2020-12	NCT01300611
ADC Therapeutics S.A.	ADCT-301	—	TERMINATED	2018-08-29	NCT02588092
ADC Therapeutics S.A.	ADCT-402	—	TERMINATED	2018-07-03	NCT02669264
ERYtech Pharma	L-asparaginase encapsulated in RBC	—	TERMINATED	2018-01-25	NCT01910428
Traws Pharma, Inc.	ON 013105	—	TERMINATED	2014-12	NCT01049113
Novartis	Gleevec/Glivec	—	TERMINATED	2011-05	NCT01066468
Merck	—	—	TERMINATED	2010-04	NCT00860535
Novartis	IMJ995 single agent	—	WITHDRAWN	2026-08-13	NCT05168748
Johnson & Johnson	JNJ-75276617	—	WITHDRAWN	2026-09-11	NCT05521087
Ossium Health, Inc.	Cyclophosphamide	DNA	WITHDRAWN	2024-03	NCT05170828

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Acute Lymphoblastic Leukemia

RET (14) FLT3 (10) FGFR (10) BCR-ABL (8) VEGFR (2)

Novel Drugs by Company (New molecular entities)

SERVIER PHARMA LLC 1 drug

ASPARLAS

CALASPARGASE PEGOL-MKNL

BLA 2018

JAZZ PHARMS 1 drug

RYLAZE

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN

SHORLA 1 drug

Amgen 1 drug

Pfizer 1 drug

INOTUZUMAB OZOGAMICIN

Merck 1 drug

Reformulations (8 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.